HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Panobinostat | Farydak | 20 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
J9223 | Lurbinectedin | Zepzelca | 0.1mg | Chemotherapy | Alkylating Agent | Adduct Forming Agent | No | 2020 | Jan 1, 2021 | In Use | ||
C9163 | Talquetamab | Talvey | 0.25mg | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
NA | Enzalutamide | Xtandi | 40 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 2012 | In Use | ||||
NA | Dasatinib | Sprycel | 140 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
S9338 | Immunotherapy - non specific | Home infusion therapy, immunotherapy | NA | Immunotherapy | No | Jan 1, 2002 | In Use | |||||
Q2054 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Sep 27, 2021 | In Use | |||
J9203 | Gemtuzumab ozogamicin | Mylotarg | 0.1 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan 1, 2018 | In Use | ||
S0108 | Mercaptopurine | Mercaptopurine | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | Yes | 1953 | Apr 1, 2002 | In Use | ||
NA | Methyltestosterone | Android, Methitest, Testred | 10 mg | Hormonal Therapy | Androgen | Yes | 1982 | In Use | ||||
NA | Thalidomide | Thalomid | 100 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
NA | Pirtobrutinib | Jaypirca | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2023 | In Use | |||
NA | Ketoconazole | Apo-Ketoconazole | 200 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Imidazole Derivative | Yes | 1981 | In Use | |||
J2930 | Methylprednisolone Sodium Succinate | A-Methapred, SOLU-medrol | 125 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Jan 1, 1997 | Apr 17, 2024 | No Longer Used | |
J1010 | Methylprednisolone acetate | Methylprednisolone acetate | 1mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Apr 17, 2024 | In Use | ||
J9357 | Valrubicin | Valstar | 200 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1998 | Jan 1, 2000 | In Use | ||
NA | lenvatinib | Lenvima | 4 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET | Yes | 2015 | In Use | |||
NA | venetoclax | Venclexta | 100 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | Cedazuridine and Decitabine | Inqovi | 100mg, 35mg | Chemotherapy | Antimetabolite | Pyrimidine Analog + CDA Inhibitor | Yes | 2020 | In Use | |||
C9215 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Feb 12, 2004 | Dec 31, 2004 | No Longer Used | |
NA | Sunitinib malate | Sutent | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
J9266 | Pegaspargase | Oncaspar | unspecified | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1996 | In Use | ||
Q5111 | Pegfilgrastim-cbqv | Udenyca | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2019 | Jan 1, 2019 | In Use | ||
NA | lenvatinib | Lenvima | 10 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET | Yes | 2015 | In Use | |||
J9380 | Teclistamab cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Jul 11, 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.